Life Sciences

  • June 05, 2026

    J&J Cleared Of Talc Liability In LA Bellwether Trial

    A Los Angeles jury cleared Johnson & Johnson of any liability in the deaths of three women from ovarian cancer, finding Friday following a six-week bellwether trial that the company's sales of talcum powder were not negligent. 

  • June 05, 2026

    IRhythm Inks $45M Deal With Investors In Heart Device Suit

    IRhythm Technologies Inc. investors asked a California federal judge to preliminarily greenlight a $45 million settlement resolving allegations the digital healthcare company inflated stock prices with misrepresentations about its heart-event monitoring device, noting the deal is a favorable result that warrants approval, given the possibility of no recovery. 

  • June 05, 2026

    Fed. Circ. Backs Melinta Patent Win In Injections Case

    Nexus Pharmaceuticals lost its appeal of an Illinois federal judge's finding that it infringed a pair of patents relating to a line of injections that treat infections, after the Federal Circuit on Friday shot down the drugmaker's challenge to the lower court's interpretation of key patent terms.

  • June 05, 2026

    Sanofi Eczema Drug Suits Consolidated, Sent To NJ Fed Court

    The Judicial Panel on Multidistrict Litigation has sent to federal court in New Jersey suits against Regeneron Pharmaceuticals and Sanofi-Aventis alleging the eczema drug Dupixent causes a rare type of non-Hodgkin lymphoma.

  • June 05, 2026

    CMS Hemp Program Foes Take Standing Fight To DC Circ.

    A group challenging a Centers for Medicare & Medicaid Services program to give patients access to federally legal hemp products will bring their case to the D.C. Circuit Court of Appeals after a federal judge tossed their petition for lack of standing last month.

  • June 05, 2026

    Health Funds Ink $5.5M Generic Drug Deal With Breckenridge

    A proposed class of end-payers who allegedly overpaid for generic drugs have asked a federal court for preliminary approval of a $5.5 million settlement with Breckenridge Pharmaceutical Inc., though notifying class members and seeking final approval would wait until the process could be combined with another settlement, the plaintiffs said Thursday.

  • June 05, 2026

    Don't Miss It: Hogan Lovells, Cooley Steer Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple of weeks, and it's difficult to keep up with all the deals.

  • June 05, 2026

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen the U.K.'s oldest Indian restaurant launch an appeal against King Charles III's property company in an effort to stop its eviction, trustees of a bankrupt former EY tax partner file a claim against his wife, and 37 leading insurers bring a lawsuit against agrichemical company Syngenta over an insurance dispute. Here, Law360 looks at these and other new claims in the U.K.

  • June 04, 2026

    No 'Conspiracy To Hide Asbestos' In Talc, J&J Atty Tells Jury

    An attorney for Johnson & Johnson said Thursday during closing arguments of a six-week bellwether trial that the only way three women's deadly ovarian cancers were caused by the company's talc would be a vast worldwide conspiracy to hide that asbestos is present in the products, but it just "doesn't make sense."

  • June 04, 2026

    Generics Cos. Get More Freedom In High Court Patent Ruling

    The U.S. Supreme Court's decision Thursday shutting down a patent case involving a generic heart drug that uses a so-called skinny label establishes a road map for generics companies to avoid such suits and creates hurdles for branded companies pursuing infringement litigation, attorneys say.

  • June 04, 2026

    Amgen Won't Face 'Nonsensical' Rodent Antibody IP At Trial

    A Delaware federal judge has trimmed Harbour Medical's infringement suit against an Amgen unit just days before trial, saying two of the company's mouse antibody patents are indefinite based on a term that "everyone agrees" is "nonsensical."

  • June 04, 2026

    Eli Lilly's 'Overbroad' Weight Drug TM Deal Rejected

    A Washington federal judge has refused to sign off on a deal to settle trademark claims brought by Eli Lilly against two Seattle-area medical clinics, saying the associated consent decree was "overbroad" and contained an even more sweeping injunction.

  • June 04, 2026

    Doctor Lied About Risky 'Basket Weave' Surgery, Patients Say

    Six patients accused a Seattle doctor of overstating his "basket weave" surgery technique meant to treat a painful condition known as "slipping rib syndrome," claiming in a Washington state lawsuit that Dr. Madhankumar Kuppusamy failed to disclose the experimental nature of the procedure that left some patients with serious injuries.

  • June 04, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    New York lawmakers gave final approval to legislation designed to curb the flow of illicit product into the state's cannabis market; Iowa's governor signed into law a bill to double the number of licensed medical cannabis dispensaries; and Louisiana legislation allowing terminally ill patients to access medical marijuana became law. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • June 04, 2026

    Fed. Circ. Invalidates Spinal Implant Patent Claims

    The Federal Circuit on Thursday invalidated patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc. and that had been upheld by the Patent Trial and Appeal Board.

  • June 04, 2026

    Judge Questions Fees In Abbott Investors' $40M Formula Deal

    An Illinois federal judge on Thursday granted final approval to most of Abbott Laboratories' $40 million deal to resolve shareholder claims over its management of a 2022 infant formula crisis, but questioned whether the settlement's corporate reforms justify a $15 million fee award for the investors' attorneys.

  • June 04, 2026

    Inotiv Gets Cash Access To Pursue Ch. 11 Prepack Track

    Bankrupt drug research and development company Inotiv Inc. received interim approval on Thursday to access a $25 million bankruptcy loan as it pursues a prepackaged balance sheet restructuring in Texas court.

  • June 04, 2026

    Catalent Investors Say No Objections To $78M Deal, Fee Bid

    Investors seeking final approval of a $78 million securities fraud settlement with Catalent told a New Jersey federal court that the proposed deal and fee bid are free of objections, arguing the positive response further supports the court's approval of the settlement.

  • June 04, 2026

    US Middle Market PE Surge Expected After Strong 2025

    U.S. middle market private equity dealmakers are signaling renewed optimism, with the vast majority expecting a meaningful jump in buyout activity over the next two years after a robust 2025, according to survey results published on Thursday. 

  • June 04, 2026

    Supreme Court Shuts Down 'Skinny Label' Drug Patent Suit

    The U.S. Supreme Court on Thursday ended a patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, saying Amarin Pharma Inc. had not plausibly alleged that Hikma encouraged healthcare providers to infringe its patents.

  • June 03, 2026

    AbbVie Loses Miss. Discount Drug Law Challenge For Good

    A Mississippi federal judge on Wednesday threw out a suit brought by AbbVie and other pharmaceutical manufacturers that participate in Medicaid challenging a law barring their interference with the distribution of discounted prescriptions to pharmacies serving low-income patients.

  • June 03, 2026

    Medtronic Unit Must Face Bellwether Hernia Mesh Claims

    A Massachusetts federal judge has largely cleared the way for bellwether claims in multidistrict litigation over Covidien's hernia mesh, finding that a reasonable jury could find the Medtronic subsidiary failed to adequately warn physicians about certain risks.

  • June 03, 2026

    Balwani Takes Theranos Conviction Challenge To Justices

    Former Theranos executive Ramesh "Sunny" Balwani is asking the U.S. Supreme Court to review his criminal fraud conviction and nearly 13-year prison sentence, arguing that the Ninth Circuit used the wrong review doctrine in rejecting his argument that prosecutors had failed to correct allegedly false testimony given by investor victims.

  • June 03, 2026

    'This Is Their Document': Jury Told J&J Docs Prove Talc Lies

    Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.

  • June 03, 2026

    Squires Institutes 3 Patent Reviews, Denies 3 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted three requests for review of patents under the America Invents Act, while turning down three other petitions.

Expert Analysis

  • Getting The Most Out Of Learning And Development Programs

    Excerpt from Practical Guidance
    Author Photo

    Junior associates can better develop the legal, business and interpersonal skills they need for long-term success by approaching their firms’ learning and development programs armed with five tips for getting the most out of these resources, says Lauren Hakala at Reed Smith.

  • Opinion

    AI Presents A Make-Or-Break Moment For Outside Counsel

    Author Photo

    The rapid adoption of artificial intelligence by corporate legal departments is forcing a long-overdue reset of the relationship between inside and outside counsel, and introducing a significant opportunity to shed frustrating inefficiencies and strengthen collaboration for firms willing to embrace the shift, says Intel Chief Legal Officer April Miller Boise.

  • Opinion

    USPTO Has A Chance To Correct Double-Patenting Doctrine

    Author Photo

    Now that the issue of obviousness-type double patenting is front and center before the U.S. Patent and Trademark Office's Appeals Review Panel, the agency should put an end to the practice of rejecting earlier-expiring patents in favor of later-expiring ones, say attorneys at Orrick.

  • Navigating Life Sciences Deals Amid Heightened Scrutiny

    Author Photo

    With pricing reform initiatives, national security legislation and evolving trade policy currently contributing to meaningful uncertainty for life sciences companies, it is important to proactively structure deals to avoid downstream complications, say attorneys at Cooley.

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.